信立泰(002294.SZ)2020年淨利降91.49%至6086.50萬元
格隆匯3月29日丨信立泰(002294.SZ)披露2020年年度報吿，報吿期內，公司實現營業總收入27.39億元，同比減少38.74%；歸屬於上市公司股東的淨利潤6086.50萬元，同比減少91.49%；經營活動產生的現金流量淨額13.74億元，同比減少8.78%；研發費用3.71億元，佔營收比重13.55%，銷售費用8.99億元，佔營收比重32.83%。
目前，自主研發的1類新藥S086已完成I期臨牀試驗，其中高血壓適應症完成II期臨牀入組，已納入230多例高血壓受試者；心衰適應症處於Ib期臨牀階段。2類新藥阿利沙坦酯氨氯地平片(SAL0107)正處於I/III期臨牀階段，進展順利；阿利沙坦酯吲達帕胺緩釋片(SAL0108)已於2021年1月收到CDE的臨牀試驗受理通知書，正在審評中。抗心衰創新生物藥JK07中美雙報獲批開展I期臨牀，目前美國I期臨牀已完成首例受試者入組；國內遺傳辦已審批公示，公司與多家中國心腦血管專科領域的知名醫院進行了初步溝通，準備開展臨牀合作。腎性貧血小分子口服制劑恩那司他片(SAL0951)目前完成I期、正在開展III期臨牀試驗，預計將是國內第二個上市的HIF-PHI藥物。
醫療器械項目研發也已逐現成效。為了讓醫療器械板塊有更好的發展前景，已啟動分拆境內上市的前期籌備工作。報吿期內，創新器械Maurora®雷帕黴素藥物洗脱椎動脈支架系統獲批，於2021年1月開始銷售；PTCA球囊導管獲得註冊批件。左心耳封堵器已完成臨牀隨訪，進展順利；“雷帕黴素藥物塗層外周血管擴張球囊導管”完成臨牀試驗備案，啟動臨牀試驗入組；GSTREAM®雷帕黴素藥物洗脱外周血管支架系統順利完成FIM臨牀試驗入組。
而受到冠脈支架全國集採未中標影響，公司根據《企業會計準則》、《會計監管風險提示第8號——商譽減值》等規定，對蘇州桓晨計提商譽減值2.83億元。計提完成後，蘇州桓晨的商譽賬面價值為0元。
報吿期內，公司引入戰略投資者——凱雷投資集團，進一步改善公司治理，為公司注入新的活力；同時，啟動非公開發行股票事宜(目前已取得批文)，為創新研發提供充裕的資金保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
